Vanderbilt Vaccine Center
Vanderbilt vaccine pioneer James Crowe honored with major science prize
Jul. 9, 2019—James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, will be honored today by the science and technology company Merck KGaA, Darmstadt, Germany for his contributions to developing new therapeutics and vaccines against some of the world’s deadliest viruses.
New method tested to block chikungunya infection
Jun. 14, 2019—Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies.
VUMC joins international effort to speed vaccine development
Jun. 6, 2019—VUMC has joined an international effort to streamline and accelerate development of vaccines and other treatments against a growing worldwide surge of deadly and debilitating viral infections.
Flu’s “hidden target” may lead to universal vaccine: study
May. 16, 2019—The flu mutates so quickly that we need a new vaccine every year, but Vanderbilt scientists have found a vulnerable part of the virus that doesn't mutate as much.
Vanderbilt Vaccine Center Seminar Series: Brandon DeKosky May 6
Apr. 30, 2019—The Vanderbilt Vaccine Center Seminar Series presents Brandon DeKosky, assistant professor of chemical engineering and pharmaceutical chemistry at the University of Kansas, on Monday, May 6.
VUMC chikungunya antibody set to enter clinical trial
Feb. 21, 2019—A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial.
Researchers push forward frontiers of vaccine science
Feb. 13, 2019—Using sophisticated gene sequencing and computing techniques, Vanderbilt researchers have achieved a first-of-its-kind glimpse into how the body’s immune system gears up to fight off infection.
Designing antibodies to fight the flu
Jan. 31, 2019—James Crowe Jr. and colleagues have developed a new computational method that may allow researchers to develop flu antibodies that can protect against more strains of the disease.
VUMC scientists ‘sprint’ to find anti-Zika antibodies
Jan. 25, 2019—Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.
Discovery could lead to neutralizing West Nile virus
Dec. 7, 2018—Research led by James Crowe, Jr., could lead to the first effective treatment for this dangerous mosquito-transmitted infection.
Team isolates antibodies that neutralize GI bug norovirus
Aug. 30, 2018—The discovery of these antibodies could significantly improve the diagnosis and treatment of the leading cause of stomach illness in the world.
Poster session Friday will feature work on next-gen vaccines
Aug. 6, 2018—The computer-aided design and engineering of antibodies and vaccine candidates that can neutralize viral scourges like influenza and Ebola will be the topic of an Aug. 17 poster session presented by the Vanderbilt Center for Structural Biology and the Vanderbilt Vaccine Center.